2017
Abnormal esophageal acid exposure on high‐dose proton pump inhibitor therapy is common in systemic sclerosis patients
Stern EK, Carlson DA, Falmagne S, Hoffmann AD, Carns M, Pandolfino JE, Hinchcliff M, Brenner DM. Abnormal esophageal acid exposure on high‐dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterology & Motility 2017, 30 PMID: 29110377, PMCID: PMC5771836, DOI: 10.1111/nmo.13247.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsAcid exposure timeEsophageal acid exposureSystemic sclerosis patientsHigh-dose proton pump inhibitorsEsophageal pH-impedance testingGastro-esophageal reflux diseasePH-impedance testingSSc patientsSystemic sclerosisSclerosis patientsAcid exposurePPI therapyHigh-dose proton pump inhibitor therapyAbnormal esophageal acid exposureCase-control retrospective analysisHigh-dose PPI therapyHigher acid exposure timeHigh-resolution manometry findingsTotal acid exposure timeProton pump inhibitor therapyTwice-daily proton pump inhibitorsHiatal hernia sizeNon-SSc patientsRheumatology SSc criteria
2016
Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study
Richardson C, Agrawal R, Lee J, Almagor O, Nelson R, Varga J, Cuttica MJ, Dematte J, Chang RW, Hinchcliff ME. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. Seminars In Arthritis And Rheumatism 2016, 46: 109-114. PMID: 27033049, PMCID: PMC5500283, DOI: 10.1016/j.semarthrit.2016.02.004.Peer-Reviewed Original ResearchConceptsRadiographic interstitial lung diseaseSSc interstitial lung diseaseInterstitial lung diseaseSystemic sclerosisCross-sectional studyEsophageal diameterEsophageal dilatationLung diseaseProgression of ILDSSc disease subtypesPulmonary function testsRodnan skin scoreErythrocyte sedimentation rateSecondary outcome variablesBody mass indexGround-glass opacitiesProton pump inhibitorsLow lung volumesSemi-quantitative scoreRegistry patientsDisease durationLow DLCOSkin scoreMedication useSerum autoantibodies
2014
Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis
Carlson DA, Hinchcliff M, Pandolfino JE. Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis. Current Rheumatology Reports 2014, 17: 475. PMID: 25475597, PMCID: PMC4343525, DOI: 10.1007/s11926-014-0475-y.Peer-Reviewed Original ResearchConceptsSystemic sclerosisEsophageal diseaseAbnormal esophageal acid exposureGastroesophageal reflux disease treatmentSymptoms of heartburnEsophageal acid exposureProton pump inhibitorsEsophageal dysmotilityPump inhibitorsGERD managementObjective findingsReflux monitoringClinical characterizationEndoscopic ultrasoundAcid exposureImpedance planimetryDiagnostic testingDiseaseDisease treatmentSclerosisPatientsTreatmentDysmotilityHeartburnDysphagia